FinanceCity
HealthcareNSE · BSE

Zydus Lifesciences Limited

ZYDUSLIFE · ISIN INE010B01027

Share price

₹1,077 -1.02%

Market capitalisation

₹1.08L CrClosed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹1.08L Cr

Current price

₹1,077

-1.02% today

52W high

₹1,120

52W low

₹836

Stock P/E

21.52

P/B ratio

4.28

02 · Per share & returns

EPS (TTM)

₹50.05

Book value

₹251

ROE

18.32%

ROA

8.07%

Dividend yield

0.09%

Beta

0.4

03 · Financials (TTM)

By the numbers

Revenue

₹27148 Cr

+16.20% YoY

EBITDA

₹7258 Cr

Net profit

₹5040 Cr

+8.70% YoY

Profit margin

18.57%

Operating margin

18.47%

Total debt

₹12496 Cr

Total cash

₹7192 Cr

Debt / equity

0.42x

Current ratio

1.27x

Payout ratio

21.96%

04 · Analyst view

Target price

₹1,067

Upside

-0.97%

Consensus

HOLD

Analysts

30

05 · Shareholding pattern

Who owns ZYDUSLIFE?

  • Promoters

    75.00%

    Founders & promoter group

  • Institutions

    15.11%

    FII + DII

  • Public

    9.89%

    Retail & non-institutional

As of 31 Mar 2026 · Source: NSE corporate filings

06 · Registration & listing

On the record

Symbol
ZYDUSLIFE
Exchange
NSE · BSE
CIN
ISIN
INE010B01027
BSE code
532321
Sector
Healthcare
Industry
Healthcare
Face value
₹1
Listing date
17 Apr 2000
Employees
Headquarters
Ahmedabad, India

07 · About

What is Zydus Lifesciences Limited?

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

08 · Common questions

Frequently asked

What is the CIN of Zydus Lifesciences Limited?+

The Corporate Identity Number for Zydus Lifesciences Limited is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of Zydus Lifesciences Limited?+

Promoter holding in ZYDUSLIFE is approximately 75.00%, as disclosed in the latest published shareholding pattern.

What is the market capitalisation of Zydus Lifesciences Limited?+

Zydus Lifesciences Limited (ZYDUSLIFE) has a market capitalisation of approximately ₹1.08L Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent

Other healthcare listings

Full sector →